Issue: April 2010
April 01, 2010
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
CSPS II
Post-Marketing Study of Cilostazol II Trial assessed safety and effi cacy of cilostazol vs. aspirin for the prevention of recurrent stroke.
Issue: April 2010
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Design: randomized, double blind, prospective
Patients: 2,757
Centers: multicenter
Country: Japan
RESULTS: Stroke was reported in 82 of 1,337 patients in the cilostazol group vs. 119 of 1,335 in the aspirin group (HR=0.743; 95% CI, 0.564-0.981). The time to stroke from initiation of administration was also longer in the cilostazol group, the researchers reported (P=.0357). Intracranial hemorrhage, subarachnoid hemorrhage or hemorrhage requiring hospitalization occurred in 23 of 1,337 patients in the cilostazol group vs. 57 of 1,335 patients in the aspirin group (P=.0004), although minor adverse effects were observed in the cilostazol group.
Presented at ISC 2010.
Click here to read more about the CSPSII trial.